Effect of edaravone in diabetes mellitus-induced nephropathy in rats.
10.4196/kjpp.2016.20.4.333
- Author:
Rajavel VARATHARAJAN
1
;
Li Xin LIM
;
Kelly TAN
;
Chai Sze TAY
;
Yi Leng TEOH
;
Shaikh Sohrab AKHTAR
;
Mani RUPESHKUMAR
;
Ivy CHUNG
;
Nor Azizan ABDULLAH
;
Urmila BANIK
;
Sokkalingam A DHANARAJ
;
Pitchai BALAKUMAR
Author Information
1. Pharmacology Unit, Faculty of Pharmacy, AIMST University, Semeling, 08100 Bedong, Kedah Darul Aman, Malaysia. varadharajeen@gmail.com
- Publication Type:Original Article
- Keywords:
Diabetic nephropathy;
Edaravone;
Lipid alteration;
Renoprotection
- MeSH:
Animals;
Body Weight;
Creatinine;
Diabetes Mellitus;
Diabetes Mellitus, Experimental;
Diabetic Nephropathies;
Glucose;
Kidney;
Lipoproteins, HDL;
Lisinopril;
Rats*;
Streptozocin;
Triglycerides;
Urea;
Vascular Resistance
- From:The Korean Journal of Physiology and Pharmacology
2016;20(4):333-340
- CountryRepublic of Korea
- Language:English
-
Abstract:
Edaravone, a synthetic-free radical scavenger, has been reported to reduce ischemia-reperfusion-induced renal injury by improving tubular cell function, and lowering serum creatinine and renal vascular resistance. The present study investigated the effect of edaravone in diabetes mellitus-induced nephropathy in rats. A single administration of streptozotocin (STZ, 55 mg/kg, i.p.) was employed to induce diabetes mellitus in rats. The STZ-administered diabetic rats were allowed for 10 weeks to develop nephropathy. Mean body weight, lipid alteration, renal functional and histopathology were analysed. Diabetic rats developed nephropathy as evidenced by a significant increase in serum creatinine and urea, and marked renal histopathological abnormalities like glomerulosclerosis and tubular cell degeneration. The kidney weight to body weight ratio was increased. Moreover, diabetic rats showed lipid alteration as evidenced by a signifi cant increase in serum triglycerides and decrease in serum high-density lipoproteins. Edaravone (10 mg/kg, i.p., last 4-weeks) treatment markedly prevented the development of nephropathy in diabetic rats by reducing serum creatinine and urea and preventing renal structural abnormalities. In addition, its treatment, without significantly altering the elevated glucose level in diabetic rats, prevented diabetes mellitus-induced lipid alteration by reducing serum triglycerides and increasing serum high-density lipoproteins. Interestingly, the renoprotective effect of edaravone was comparable to that of lisinopril (5 mg/kg, p.o, 4 weeks, standard drug). Edaravone prevented renal structural and functional abnormalities and lipid alteration associated with experimental diabetes mellitus. Edaravone has a potential to prevent nephropathy without showing an anti-diabetic action, implicating its direct renoprotection in diabetic rats.
